Australia's most trusted
source of pharma news
Thursday, 30 October 2025
Posted 30 October 2025 AM
Johnson & Johnson Innovative Medicine has taken steps to protect a $74 million franchise from early competition.
A lawsuit filed in the Federal Court under the former name of J&J's pharmaceutical arrm, Janssen, claims that Juno has threatened to infringe a patent protecting its schizophrenia treatments by ignoring its request for an undertaking that Juno would not supply or cause the PBS listing of any of its products in Australia before the expiry of the patent.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.